58966-35-1

Usage

Uses

Used in Organic Synthesis:
1-(5-chloro-2-Methylphenyl)ethan-1-one is used as a building block in organic synthesis for the creation of a variety of compounds. Its unique structure and properties make it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(5-chloro-2-Methylphenyl)ethan-1-one is utilized as a key intermediate in the development of new drugs. Its chemical properties allow it to be incorporated into the molecular structures of potential therapeutic agents, contributing to the advancement of medicinal chemistry.
Used in Chemical Production:
1-(5-chloro-2-Methylphenyl)ethan-1-one is employed in the production of various chemical products, including agrochemicals, dyes, and other specialty chemicals. Its versatility and reactivity make it a valuable component in the synthesis of a wide range of chemical products.
Used in Research and Development:
1-(5-chloro-2-Methylphenyl)ethan-1-one is also used in research and development settings to explore its potential applications and properties. Scientists and researchers utilize 1-(5-chloro-2-Methylphenyl)ethan-1-one to investigate its reactivity, stability, and potential uses in various chemical and pharmaceutical processes.

Upstream product

• 27139-97-5 2-bromo-4-chloro-1-methyl-benzene 
• 75-36-5 acetyl chloride 
• 50712-70-4 5-chloro-2-methylbenzonitrile 
• 74-88-4 methyl iodide 
• 75-16-1 methylmagnesium bromide 
• 917-64-6 methyl magnesium iodide 

Downstream Products

• 58966-31-7 (+/-)-α-(2-Methyl-5-chlorphenyl)-aethylalkohol 
• 74331-72-9 1-(5-Chloro-2-methylphenyl)acetylene 
• 74346-29-5 1-(5-Chloro-2-methylphenyl)vinyl bromide 
• 74346-28-4 1-(5-Chloro-2-methylphenyl)vinyl tosylate 
• 1617523-16-6 C₁₃H₁₃ClO₄ 
• 58966-44-2 (+/-)-α-(2-Methyl-5-chlorphenyl)-aethanthiol 
• 58966-32-8 (+/-)-α-(2-Methyl-5-chlorphenyl)-aethylbromid 

Relevant academic research and scientific papers

Pyrazolyl-Based Carboxamides II

The invention relates to pyrazolyl-based carboxamide compounds useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

PYRAZOLYL-BASED CARBOXAMIDES II AS CRAC CHANNEL INHIBITORS

The invention relates to pyrazolyl-based carboxamide compounds of formula (I) useful as ICRAC inhibitors, to pharmaceutical compositions containing these compounds and to these compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders, in particular inflammatory diseases and/or inflammatory disorders.

PYRROLO [1, 2-A] PYRAZINE DERIVATIVES AS VASOPRESSIN VIB RECEPTOR ANTAGONISTS

The present invention relates to novel compounds of formula (I) or salts thereof; wherein R is -X-[CH2]nCR4R5-Y; or a group G; R1 is H or C1 -C4 alkyl; R2 is aryl, heteroaryl or C3-C7 cycloalkyl, which may be substituted with one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, - CN; R3 is -CH2-C(=O)-NH-R6; X is -CR7R8-, -O-, -NR9-, -S-; Y is-NR10R11 R4 is H or C1 -C4 alkyl; R5 is H or C1 -C4 alkyl; R6 is C1-C6 alkyl, C3-C6 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R7 is H or C1 -C4 alkyl; R8 is H or C1 -C4 alkyl; R9 is H or C1 -C4 alkyl; R10 is H or C1-C4 alkyl, or together with R11 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR12; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R11 is H or C1 -C4 alkyl; R12 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; G is one of the groups selected from the list consisting of G1, G2, G3, G4, G5, G6, G7, G8, G9, G10, G11 and G12; R 13 is H or C1-C4 alkyl, or together with R14 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR24; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R14 R16 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R15, R 17 correspond to H or C1-C4 alkyl and may assume different meanings; R 18 is H or C1-C4 alkyl, or together with R17 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR25; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R19, R20, R21, R22, R23, R24, R25 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R26, R27, R28, R29 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; I, I' correspond to 1 or 2 and may assume different meanings; m, m', m", m"', mιv, mv correspond to 0, 1 or 2 and may assume different meanings; n is 1, 2 or 3; q is 1, 2 or 3; p, p', p", p'" correspond to 0, 1, 2 or 3 and may assume different meanings; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as antagonists of V1b receptors, e.g. to treat depression and anxiety.

PHTHALAZINONES

The invention relates to compounds of formula I, wherein R, R1, R2, R3, R4, R5, R6, R7, R8, Z1, Z2, Z3 and Y1 have the mean

Elevation of HDL cholesterol by 2-[(aminothioxomethyl)-hydrazono]-2-arylethyl carbamates

This invention relates to the treatment of atherosclerosis via raising the level of HDL cholesterol by administration of a compound of the formula STR1 wherein: R1, R2, and R3 are independently hydrogen, C1 -C6 alkyl or --(CH2)0-6 Ph where Ph is phenyl optionally substituted by halogen, cyano, nitro, C1 -C6 alkyl, C1 -C6 alkoxy, trifluoromethyl, C1 -C6 alkoxycarbonyl, --CO2 H or OH; R4 and R5 are independently hydrogen, C1 -C6 alkyl, C3 -C8 cycloalkyl, or --(CH2)0-6 Ar1 where Ar1 is phenyl, naphthyl, furanyl, pyridinyl or thienyl and Ar1 can be optionally substituted by halogen, cyano, nitro, C1 -C6 alkyl, phenyl, C1 -C6 alkoxy, phenoxy, trifluoromethyl, C1 -C6 alkoxycarbonyl, --CO2 H or OH; and Ar is phenyl, naphthyl, furanyl, pyridinyl or thienyl or Ar is optionally substituted by halogen, cyano, nitro, C1 -C6 alkyl, C3 -C6 cycloalkyl, phenyl, C1 -C6 alkoxy, phenoxy, trifluoromethyl, C1 -C6 alkoxycarbonyl, --CO2 H or OH.

Vinyl Cation Intermediates in Solvolytic and Electrophilic Reactions. 1. Solvolysis of α-Arylvinyl Derivatives

The solvolysis of 16 α-arylvinyl tosylates, bromides, and chlorides has been investigated in various alcohol-water mixtures and in acetic acid at several temperatures.All substrates were substituted with either 2-methyl or 2,6-dimethyl groups to accelerate the rates of reaction.The major or exclusive product isolated in most cases was the acetophenone arising from hydrolysis of the expected enol ethers or acetates during workup.The kinetics were simple first order in the vast majority of cases, with excess base added to prevent side reactions.Leaving group effects, Winstein-Grunwald m values, Schleyer Q values, and effects of solvent nucleophilicity all point to a limiting SN1 ionization generating a vinyl cation intermediate, in which there is little rear-side nucleophilic assistance by solvent.Substituent effects led to ρ values in the range -3.9 to -5.3 vs. ?+.Activation parameters are typical for an SN1 process, and ΔS% is insensitive to the presence of zero, one, or two o-methyl groups, as are the effects of solvent polarity on the rates.The results should therefore be directly comparable with other solvolytic or electrophilic reactions generating formally similar vinyl cation intermediates.